Addex gets $1M MJFF grant to test potential dyskinesia drug

03/20/2013 | Pharmaceutical Business Review Online

The Michael J. Fox Foundation awarded Addex Therapeutics a $1 million grant to support clinical trials of dipraglurant against levodopa-induced dyskinesia among Parkinson's disease patients. Dipraglurant, an oral, small molecule allosteric modulator, selectively inhibits metabotropic glutamate receptor 5.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care